MARKET

ISEE

ISEE

IVERIC bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.31
-0.06
-1.12%
After Hours: 5.37 +0.06 +1.13% 17:00 01/22 EST
OPEN
5.33
PREV CLOSE
5.37
HIGH
5.37
LOW
5.20
VOLUME
848.14K
TURNOVER
--
52 WEEK HIGH
7.98
52 WEEK LOW
2.640
MARKET CAP
475.60M
P/E (TTM)
-4.1686
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.
Business Wire · 01/05 13:00
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.
Business Wire · 12/17/2020 13:00
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021...
BusinessWire · 12/17/2020 10:00
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.
Business Wire · 12/04/2020 13:00
Family Vision Practice Merges with Sterling Vision
, /PRNewswire/ -- Sterling Vision is pleased to announce the addition of Family Vision Practice to our network. Family Vision Practice is located in , and has been the practice of Dr. for the past 39 years. "I have selected Sterling Vision to assume my practice effective so I can work part-time as a deacon at the St. Anthony of Padua Catholic Church," says Dr. Krebsbach. "I am confident that the Sterling Vision team will create a friendly and professional atmosphere that my patients can rely on for all of their eye health needs."
PR Newswire - PRF · 11/12/2020 16:00
Family Vision Practice Merges with Sterling Vision
, /PRNewswire/ -- Sterling Vision is pleased to announce the addition of Family Vision Practice to our network. Family Vision Practice is located in , and has been the practice of Dr. for the past 39 years. "I have selected Sterling Vision to assume my p...
PR Newswire - PRF · 11/12/2020 16:00
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 11/03/2020 12:45
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Simply Wall St. · 11/03/2020 12:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISEE. Analyze the recent business situations of IVERIC bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ISEE stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 170
Institutional Holdings: 82.63M
% Owned: 92.26%
Shares Outstanding: 89.57M
TypeInstitutionsShares
Increased
48
9.10M
New
40
-4.23M
Decreased
25
5.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Executive Director
David Guyer
President/Chief Executive Officer/Director
Glenn Sblendorio
Chief Financial Officer/Senior Vice President/Treasurer
David Carroll
Chief Operating Officer/Senior Vice President
Keith Westby
Chief Scientific Officer
Abraham Scaria
Lead Director/Independent Director
Adrienne Graves
Director
Mark Blumenkranz
Independent Director
Axel Bolte
Independent Director
Jane Henderson
Independent Director
Calvin Roberts
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ISEE
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company’s therapeutics portfolio consists of its clinical stage product candidate Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, its preclinical product candidate from its High temperature requirement A serine peptidase one protein (HtrA1), inhibitors program. Its lead gene therapy products also includes IC-100 and IC-200.
More

Webull offers kinds of IVERIC bio Inc stock information, including NASDAQ:ISEE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISEE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISEE stock methods without spending real money on the virtual paper trading platform.